To develop an NK cell-based immunotherapy for HCC patients, we genetically engineered NK92MI cells with the third-generation CAR molecules, HN3 or HS20, which specifically target GPC3, a highly expressed antigen in HCC. The gene discussed is GPC3; the disease is hepatocellular carcinoma.